The patient required a blood
transfusion during surgery.
这位病人在手术中需要输血。
She donated blood for the first time and felt proud of her contribution to a life-saving
transfusion.
她第一次捐血，为自己的贡献能挽救生命感到自豪。
After the accident, he received an emergency
transfusion of plasma to stabilize his condition.
事故发生后，他接受了紧急的血浆输注以稳定病情。
The doctors advised a red blood cell
transfusion to boost his oxygen-carrying capacity.
医生建议输红细胞以提高他的携氧能力。
His low hemoglobin levels necessitated regular
transfusions to maintain his health.
他的血红蛋白水平低下，需要定期输血来维持健康。
In some cases, a platelet
transfusion is necessary to prevent excessive bleeding.
在某些情况下，需要输注血小板以防止过度出血。
The patient's body rejected the transfused blood, causing an adverse reaction.
病人对输入的血液产生了排斥反应，导致了不良反应。
Blood
transfusions can be life-saving in cases of severe anemia or hemorrhage.
对于严重贫血或大出血的情况，输血可以挽救生命。
The hospital maintains a strict protocol for blood
transfusions to ensure safety.
医院对输血有严格的操作规程，以确保安全。
A plasma
transfusion was administered to help combat the effects of the virus.
输入血浆以帮助对抗病毒的影响。
Another major exhibit by the company is its world‘s first erythroid maturation agent called Luspatercept, which reduces patients' transfusion burden and is the first treatment advancement in myelodysplastic syndromes in more than a decade.
该公司的另一个主要展品是其世界上第一种名为Luspatercept的红系成熟剂，它可以减轻患者的输血负担，是十多年来骨髓增生异常综合征的首次治疗进展。
In January 2021, the Center for Drug Evaluation of China National Medical Products Administration approved EdiGene's investigational new drug application for ET-01, an investigational CRISPR/Cas 9 gene-editing therapy for patients with transfusion dependent β-thalassemia.
2021年1月，中国国家药品监督管理局药品审评中心批准了EdiGene的ET-01临床试验申请。ET-01是一种CRISPR/Cas9基因编辑疗法，用于治疗依赖输血的β地中海贫血患者。
Chinese biotech company EdiGene Inc announced on Monday the Center for Drug Evaluation of the China National Medical Products Administration has approved the company's Investigational New Drug application for ET-01, a CRISPR/Cas 9 gene-editing therapy for patients with transfusion dependent β-thalassemia, a blood disease characterized by severe anemia and a lifelong dependence on red blood cell transfusions that can lead to iron overload.
中国生物技术公司EdiGene周一宣布，中国国家药品监督管理局药品审评中心已批准其ET-01的新药临床试验申请。ET-01是一种使用CRISPR/Cas9基因编辑技术治疗输血依赖性β地中海贫血症的疗法。该疾病是一种以严重贫血和终身依赖红细胞输血为特征的血液病，可能导致铁过载。
The approved trial of ET-01 is a multicenter, open-label, single arm study designed to assess safety and efficacy in transfusion dependent β-thalassemia patients.
ET-01的获批试验是一项多中心、开放标签、单臂研究，旨在评估输血依赖性β地中海贫血患者的疗效和安全性。
Serious unmet medical needs remain for transfusion dependent β-thalassemia patients today.
对于依赖输血的β-地中海贫血患者，目前仍有严重的未满足医疗需求。
For example, the company's Alinity™ diagnostics systems, soon to be launched in China, offer hospitals and laboratories a harmonized experience across all critical diagnostic disciplines including clinical chemistry, immunoassay, hematology, transfusion, molecular, point of care, and informatics, delivering better efficiency and flexibility to help standardize processes and reduce costs.
For example, the company's Alinity™ diagnostics systems, soon to be launched in China, offer hospitals and laboratories a harmonized experience across all critical diagnostic disciplines including clinical chemistry, immunoassay, hematology, transfusion, molecular testing, point of care and informatics, delivering better efficiency and the flexibility to help standardize processes, reduce costs and improve efficiency.
Since then, Liu said with a "blood transfusion" to the property industry, supply and demand in the market have seen noticeable improvements.
未经许可，严禁转发。QQ交流群：688169419